Hyperfine (NASDAQ:HYPR) Given “Buy” Rating at BTIG Research

Hyperfine (NASDAQ:HYPR)‘s stock had its “buy” rating reissued by BTIG Research in a report issued on Tuesday, Benzinga reports. They presently have a $2.00 target price on the stock. BTIG Research’s target price would suggest a potential upside of 156.05% from the stock’s current price.

HYPR has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperfine in a report on Friday, July 17th. B. Riley Financial reiterated a “buy” rating and set a $1.60 price objective (down from $2.00) on shares of Hyperfine in a report on Monday, August 10th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Hyperfine presently has an average rating of “Hold” and an average target price of $2.03.

Hyperfine Trading Down 0.5%

Shares of Hyperfine stock opened at $0.78 on Tuesday. Hyperfine has a fifty-two week low of $0.75 and a fifty-two week high of $2.22. The firm has a market cap of $82.84 million, a PE ratio of -2.06 and a beta of 1.41. The business’s fifty day moving average is $0.89 and its two-hundred day moving average is $1.19. The company has a quick ratio of 5.45, a current ratio of 6.15 and a debt-to-equity ratio of 0.36.

Hyperfine (NASDAQ:HYPR) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.09) EPS for the quarter, meeting analysts’ consensus estimates of ($0.09). The business had revenue of $3.90 million during the quarter, compared to the consensus estimate of $4.13 million. Hyperfine had a negative return on equity of 97.88% and a negative net margin of 210.75%. Analysts anticipate that Hyperfine will post -0.34 earnings per share for the current year.

Institutional Investors Weigh In On Hyperfine

Several institutional investors and hedge funds have recently added to or reduced their stakes in HYPR. Catalio Capital Management LP raised its holdings in shares of Hyperfine by 92.8% in the 4th quarter. Catalio Capital Management LP now owns 1,320,041 shares of the company’s stock worth $1,293,000 after purchasing an additional 635,500 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Hyperfine in the 2nd quarter valued at about $419,000. Renaissance Technologies LLC grew its holdings in shares of Hyperfine by 100.2% during the 1st quarter. Renaissance Technologies LLC now owns 730,233 shares of the company’s stock worth $789,000 after purchasing an additional 365,490 shares during the period. Finally, Walleye Capital LLC grew its holdings in shares of Hyperfine by 3.4% during the 1st quarter. Walleye Capital LLC now owns 223,988 shares of the company’s stock worth $242,000 after purchasing an additional 7,330 shares during the period. 15.03% of the stock is currently owned by institutional investors and hedge funds.

About Hyperfine

Hyperfine, Inc is a medical technology company that develops portable magnetic resonance imaging (MRI) systems for use at the point of care. Its flagship product, the Swoop Portable MR Imaging System, is designed to bring brain imaging directly to patients in settings such as intensive care units, emergency departments, hospitals and other clinical environments.

The Swoop system is intended to support rapid assessment of neurological conditions, including stroke, brain injury and other disorders.